These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 7578619

  • 1. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
    Blijenberg BG, Eman I, Boevé ER, Mössner E, Uhl W.
    Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)--multi-centre study results. The PSA Study Group.
    Schambeck CM.
    Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):541-7. PubMed ID: 8547440
    [Abstract] [Full Text] [Related]

  • 3. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 Aug; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 4. Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer.
    Blijenberg BG, Bangma CH, Kranse R, Eman I, Schröder FH.
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):111-4. PubMed ID: 9056753
    [Abstract] [Full Text] [Related]

  • 5. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
    Reiter W.
    Anticancer Res; 1999 Feb; 19(6C):5559-62. PubMed ID: 10697616
    [Abstract] [Full Text] [Related]

  • 6. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen.
    Blijenberg BG, Kessler AC, Uhl W.
    Eur J Clin Chem Clin Biochem; 1995 Dec; 33(12):965-73. PubMed ID: 8845430
    [Abstract] [Full Text] [Related]

  • 7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 8. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, Wright GL, Schellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE.
    Urology; 1997 Jan 15; 49(1):19-27. PubMed ID: 9000179
    [Abstract] [Full Text] [Related]

  • 9. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan 15; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 10. Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
    Arai Y, Onishi H, Oishi K, Takeuchi H, Yoshida O.
    Jpn J Clin Oncol; 1993 Apr 15; 23(2):110-5. PubMed ID: 7685834
    [Abstract] [Full Text] [Related]

  • 11. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J.
    J Urol; 1997 Mar 15; 157(3):913-8. PubMed ID: 9072598
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR, Lapeyrolerie T.
    J Urol; 1997 Apr 15; 157(4):1322-8. PubMed ID: 9120931
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H.
    J Urol; 1999 Apr 15; 161(4):1206-11. PubMed ID: 10081870
    [Abstract] [Full Text] [Related]

  • 17. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
    Wolff JM, Stocker G, Borchers H, Haubeck H, Greiling H, Jakse G.
    Anticancer Res; 1999 Apr 15; 19(4A):2633-6. PubMed ID: 10470208
    [Abstract] [Full Text] [Related]

  • 18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 15; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The biologic lower detection limit of six ultrasensitive PSA assays.
    Junker R, Brandt B, Semjonow A, Erren M, Zechel C, Assmann G.
    Anticancer Res; 1999 Mar 15; 19(4A):2625-8. PubMed ID: 10470206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.